Combined androgen and antimetabolite therapy of advanced female breast cancer. A report of the cooperative breast cancer group
- PMID: 1098764
- DOI: 10.1002/1097-0142(197508)36:2<308::aid-cncr2820360203>3.0.co;2-1
Combined androgen and antimetabolite therapy of advanced female breast cancer. A report of the cooperative breast cancer group
Abstract
A clinical trial of androgen and antimetabolite therapy of advanced female breast cancer was conducted in 110 patients by the Cooperative Breast Cancer Group. An objective regression rate of 20% was achieved in women receiving oral testolactone, 6% in patients given intravenous fluorouracil alone, and 14% when the androgen and antimetabolite were administered together. This randomized trial according to the CBCG protocol did not produce the high regression rate noted previously in a nonrandomized, nonprotocol evaluation of these drugs.